Agenus to Advance Three Checkpoint Modulator Antibodies into Development Wall Street Journal Ludwig Cancer Research and Agenus Inc. (NASDAQ: AGEN) today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development. These product candidates--two GITR agonists ... Ludwig and Agenus to advance three checkpoint modulator antibodies into ... Agenus reports net loss attributable to common stockholders of $5.8 million ... |
